Pml Nuclear Body Disruption Cooperates in APL Pathogenesis and Impairs DNA Damage Repair Pathways in Mice

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2017 Dec 2

PMID 29191918

Citations 26

Authors

Edwige Voisset

Eva Moravcsik

Eva W Stratford

Amie Jaye

Christopher J Palgrave

Robert K Hills

Paolo Salomoni

Scott C Kogan

Ellen Solomon

David Grimwade

Affiliations

Soon will be listed here.

Abstract

A hallmark of acute promyelocytic leukemia (APL) is altered nuclear architecture, with disruption of promyelocytic leukemia (PML) nuclear bodies (NBs) mediated by the PML-retinoic acid receptor α (RARα) oncoprotein. To address whether this phenomenon plays a role in disease pathogenesis, we generated a knock-in mouse model with NB disruption mediated by 2 point mutations (C62A/C65A) in the Pml RING domain. Although no leukemias developed in Pml mice, these transgenic mice also expressing RARα linked to a dimerization domain (p50-RARα model) exhibited a doubling in the rate of leukemia, with a reduced latency period. Additionally, we found that response to targeted therapy with all- retinoic acid in vivo was dependent on NB integrity. PML-RARα is recognized to be insufficient for development of APL, requiring acquisition of cooperating mutations. We therefore investigated whether NB disruption might be mutagenic. Compared with wild-type cells, primary Pml cells exhibited increased sister-chromatid exchange and chromosome abnormalities. Moreover, functional assays showed impaired homologous recombination (HR) and nonhomologous end-joining (NHEJ) repair pathways, with defective localization of Brca1 and Rad51 to sites of DNA damage. These data directly demonstrate that Pml NBs are critical for DNA damage responses, and suggest that Pml NB disruption is a central contributor to APL pathogenesis.

Citing Articles

Diagnostic and Therapeutic Implications of the SUMOylation Pathway in Acute Myeloid Leukemia.

Chatzikalil E, Arvanitakis K, Filippatos F, Diamantopoulos P, Koufakis T, Solomou E Cancers (Basel). 2025; 17(4).

PMID: 40002226 PMC: 11853134. DOI: 10.3390/cancers17040631.

Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RARα.

Minami M, Sakoda T, Kawano G, Kochi Y, Sasaki K, Sugio T Leukemia. 2025; .

PMID: 39979604 DOI: 10.1038/s41375-025-02530-9.

Decoding the Implications of Zinc in the Development and Therapy of Leukemia.

Zhu B, Yang C, Hua S, Li K, Shang P, Li Z Adv Sci (Weinh). 2025; 12(9):e2412225.

PMID: 39887881 PMC: 11884550. DOI: 10.1002/advs.202412225.

Biomolecular condensates in immune cell fate.

Kodali S, Sands C, Guo L, Huang Y, Di Stefano B Nat Rev Immunol. 2025; .

PMID: 39875604 DOI: 10.1038/s41577-025-01130-z.

Phase separation of PML/RARα and BRD4 coassembled microspeckles governs transcriptional dysregulation in acute promyelocytic leukemia.

Zhang Y, Lou J, Liu Y, Jin P, Tan Y, Song H Proc Natl Acad Sci U S A. 2024; 121(34):e2406519121.

PMID: 39136995 PMC: 11348160. DOI: 10.1073/pnas.2406519121.

References

Liu Z, Ren G, Shangguan C, Guo L, Dong Z, Li Y . ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene. PLoS One. 2012; 7(7):e40943. PMC: 3396626. DOI: 10.1371/journal.pone.0040943. View

Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

Zimonjic D, Pollock J, Westervelt P, Popescu N, Ley T . Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A. 2000; 97(24):13306-11. PMC: 27220. DOI: 10.1073/pnas.97.24.13306. View

Ochs F, Somyajit K, Altmeyer M, Rask M, Lukas J, Lukas C . 53BP1 fosters fidelity of homology-directed DNA repair. Nat Struct Mol Biol. 2016; 23(8):714-21. DOI: 10.1038/nsmb.3251. View

Park M, Seok Y, Jeong G, Lee J . SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy. Nucleic Acids Res. 2007; 36(1):263-83. PMC: 2248730. DOI: 10.1093/nar/gkm969. View

Munch S, Weidtkamp-Peters S, Klement K, Grigaravicius P, Monajembashi S, Salomoni P . The tumor suppressor PML specifically accumulates at RPA/Rad51-containing DNA damage repair foci but is nonessential for DNA damage-induced fibroblast senescence. Mol Cell Biol. 2014; 34(10):1733-46. PMC: 4019039. DOI: 10.1128/MCB.01345-13. View

Korf K, Wodrich H, Haschke A, Ocampo C, Harder L, Gieseke F . The PML domain of PML-RARα blocks senescence to promote leukemia. Proc Natl Acad Sci U S A. 2014; 111(33):12133-8. PMC: 4143011. DOI: 10.1073/pnas.1412944111. View

Mohrin M, Bourke E, Alexander D, Warr M, Barry-Holson K, Le Beau M . Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell. 2010; 7(2):174-85. PMC: 2924905. DOI: 10.1016/j.stem.2010.06.014. View

Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub M, Durand B . Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J. 1992; 11(2):629-42. PMC: 556495. DOI: 10.1002/j.1460-2075.1992.tb05095.x. View

10.

Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller K, Jackson S . Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature. 2009; 462(7275):935-9. PMC: 2904806. DOI: 10.1038/nature08657. View

11.

Le Beau M, Bitts S, Davis E, Kogan S . Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood. 2002; 99(8):2985-91. DOI: 10.1182/blood.v99.8.2985. View

12.

Wang Z, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C . Role of PML in cell growth and the retinoic acid pathway. Science. 1998; 279(5356):1547-51. DOI: 10.1126/science.279.5356.1547. View

13.

Galanty Y, Belotserkovskaya R, Coates J, Jackson S . RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair. Genes Dev. 2012; 26(11):1179-95. PMC: 3371407. DOI: 10.1101/gad.188284.112. View

14.

Ibanez M, Carbonell-Caballero J, Garcia-Alonso L, Such E, Jimenez-Almazan J, Vidal E . The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations. PLoS One. 2016; 11(2):e0148346. PMC: 4757557. DOI: 10.1371/journal.pone.0148346. View

15.

Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann T, Schwanitz G . Dynamics of component exchange at PML nuclear bodies. J Cell Sci. 2008; 121(Pt 16):2731-43. DOI: 10.1242/jcs.031922. View

16.

Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de The H . Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med. 2013; 210(4):647-53. PMC: 3620357. DOI: 10.1084/jem.20122337. View

17.

Chen G, Zhu J, Shi X, Ni J, Zhong H, Si G . In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88(3):1052-61. View

18.

Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A . Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016; 374(5):422-33. DOI: 10.1056/NEJMoa1507471. View

19.

Ablain J, de The H . Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011; 117(22):5795-802. DOI: 10.1182/blood-2011-02-329367. View

20.

Bunting S, Callen E, Wong N, Chen H, Polato F, Gunn A . 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010; 141(2):243-54. PMC: 2857570. DOI: 10.1016/j.cell.2010.03.012. View